-
Product Insights
NewNet Present Value Model: Nuvation Bio Inc’s NUV-868
Empower your strategies with our Net Present Value Model: Nuvation Bio Inc's NUV-868 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Nuvation Bio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Nuvation Bio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-023 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sym-023 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sym-023 in Solid Tumor Drug Details: Sym-023 is under development for the...
-
Product Insights
NewNet Present Value Model: Viking Therapeutics Inc’s VK-2809
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TEV-56248 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TEV-56248 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TEV-56248 in AsthmaDrug Details:TEV-56248 is under development for the treatment of asthma.Report CoverageThe data...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Activated T Lymphocytes in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Activated T Lymphocytes in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Activated T Lymphocytes in Hepatocellular Carcinoma Drug Details: Activated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6433 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6433 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6433 in Non-Small Cell Lung Cancer Drug Details: RG-6433 (RLY-1971)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-868 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-868 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-868 in Fallopian Tube Cancer Drug Details:NUV-868 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-868 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-868 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-868 in Triple-Negative Breast Cancer (TNBC) Drug Details:NUV-868 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-868 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-868 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-868 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:NUV-868 is...